Abiopharma

Vir Biotechnology - Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors